Deutsche Märkte schließen in 7 Stunden 2 Minuten

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
2,7700+0,0100 (+0,36%)
Börsenschluss: 04:00PM EDT
2,7700 0,00 (0,00%)
Nachbörse: 07:59PM EDT

Yahoo Finanzen Deutschland wird unser Diskussionsforum am 15. August entfernen. Vielen Dank, dass Sie so ein treues Mitglied unserer Diskussions-Community auf Yahoo Finanzen sind!

Melden Sie sich an, um eine Nachricht zu posten.
  • B
    Bruce
    $AUPH conversation
    To those who resent Ariadinvestor's counterattacks: Have you ever condemned the attackers? Have you ever condemned Yahoo Admin T/M/Rank/Billy's racial hatred against the Asians' skin color? Do you support the Verizon Yahoo Admin's racial hatred? Please answer my questions instead of changing the topic by questioning who I am. Thanks!

    Ariadinvestor claims he doesn't attack anyone unless he has been attacked first. TRUE! frankie C has resurfaced and resumed her attacks. Wayne, Ray, edward, Big Toe and Yahoo Admin Rank/Billy/Pete/T never stop their attacks. Ariadinvestor counterattacks the attackers. When will the war end? You should condemn the attackers instead of attacking the counterattackers.

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .
    cc: $AUPH $SRNE $auph $srne
    .

    Aug 26, 2021 (AB Digital via COMTEX) -- VICTORIA, British Columbia - Aurinia Pharmaceuticals (NASDAQ: $AUPH ) (the “Company”) is pleased to announce that it will enter into a definitive agreement with a pharma behemoth. The leading pharmaceutical company is in talks with AUPH for an acquisition pegged at $35 per American Depositary Share (ADS) or plus.

    On paper, the total consideration of the acquisition is estimated to come up to $4,485 billion in the form of $35 in cash ordinary shares or plus. The transaction has been said to be unanimously approved by the Board of Directors of both companies and is expected to close in the third quarter of 2021.

    “This collaboration will help us pave the way to create many more solutions in the autoimmune space and will be able to increase our marketing process” said Peter Greenleaf, President and Chief Executive Officer of Aurinia Pharmaceuticals speaking about the said merger.

    Founded in 2012, Aurinia Pharmaceuticals Inc specializes in principled drug development and commercialization in the field of autoimmune diseases. The Canadian company’s stocks are currently valued at $14.33 (as of 23 August 2021), and the values are projected to rise with the impending acquisition.

    With a market cap of $2 billion, the Company packs a lot of potential for its original solutions in the field of autoimmune diseases. The merger would come as the perfect progression to the acquiring company that is known to cashing in on strong trends to make deals of economic relevance.

    Various sources and market whispers indicated that multiple pharma companies were keen on exploring acquisition opportunities with $AUPH . However, this market leader was finally the one that converted these interests through its proposal of a tuck-in acquisition.

    Earlier this year, the acquiring company also made investments in the space of oncology. After having spent roughly $1.4 billion in milestone payments the pharma giant was exploring other investments in non-linear pharma fields. AUPH emerged as one of the safest buys on its list.

    As per this proposal, the acquisition indicates a merger of the two companies. Even though the acquiring company is capable of deploying a windfall of cash, a tuck-in acquisition seems ideal for the current market. AUPH has presented itself as the perfect option for the acquiring company to leverage the company’s skills and knowledge.

    The merger will also help $AUPH bring its deep experience in actively pursuing a broader portfolio of innovative drugs for autoimmune diseases like Lupus and Nephritis to the table. A successful tuck-in acquisition can increase revenues and broaden the acquiring company's capabilities and resources, which can effectively boost AUPH’s growth graph.

    The Company launched its first product Lupkynis in January this year. The drug that was made to treat Lupus Nephritis clocked in revenues of $6.6 million in the second quarter superseding pre-launch expectations. $SRNE short squeeze ?

    Recently the company also acquired novel pipeline assets targeting autoimmune and kidney-related diseases diversifying its portfolio of offering therapeutic solutions to people living with rare diseases.

    Once the merger with the market leader goes through, AUPH is expected to bring promising new products to the market keeping up with its offerings in the space of autoimmune diseases.

    About Aurinia

    Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

    Statutory Statement
    $SRNE
    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Excha
  • A
    Ariadinvestorg
    $AUPH conversation
    GAN has a track record of spreading false info/making false accusations. He used to post "Buyout on Monday" every Friday. He accuses Canadians of shorting AUPH. False! I, a Canadian, don't short AUPH. He accuses me of molesting the ugly children of his clan/family. False! Only Yahoo Admin T/Rank would be such a child molester.

    Dennis:
    "
    Apparently many investment strategies are based on the facial expressions of a CEO during an interview.
    "

    Jessica: “Would you like to learn how you can earn money from investing in Stocks, Forex and Binary Options? Send me a friend request if interested."

    @AUPH $SRNE short squeeze id just a matter of time.
  • A
    Ariadinvestorg
    $SRNE conversation
    To madden frankie C 👌 I swear to God that I accepted the $24/share tender offer for my 118,199+ ARIA shares (including what I bought at 0.80 in 2008) in my Fidelity accounts. Let's swear to God that I would burn in hell after dying the most painful death if I were lying here, or you will burn in hell after dying the most painful death. I learned swearing to God on ARIA message board from your husband Yahoo Admin T whose ARIA/AUPH/SRNE position was/is always opposite to mine. T has shorted both $SRNE and $AUPH at bottom prices. Just a matter of time short squeeze is !
  • A
    Ariadinvestorg
    $AUPH conversation
    @Mark 👈 Why do you want me to sue someone? Sue you? You said you made $1 million in 2021. You are saying you made $1.7 million in 2021. Won't you say you made $2.7 million in 2021? You are just a bragging clown suffering from HPD. Why would I sue you? You made a killing by shorting AUPH at $23 right before it surged to $33+? Did the short squeeze cure your HPD? You are still shouting/bragging "Watch and learn...I haven't missed a call yet." 🤣 Pathetic! Surely you're not a luser.🤣 But haven't you said your dad's a dead luser? $srne shoot sueeze ?
  • A
    Ariadinvestorg
    $AUPH conversation
    Wayne bought AUPH at $32. Winner! He capitulated? 🎈 Congratulations! 🎈 The winner says I'm a loser. 😂 The winner is right! => I started to accumulate AUPH when it was @ $2.90. I sold 100 AUPH covered calls (APR 2022 $35.00 CALL) @ $3.05. I own far more than 10,000 AUPH gold bags. I posted on 2017-11-22: "I added 7,001 shares @4.28-4.68 on 11/15/2017; 2000 shrs @5.48 11/14/17; 2000 shrs @5.66 10/26/17; 2000 shrs @5.76 10/24/17; 2000 shrs @5.98 10/23/17; 2000 shrs @6.13 10/20/17; ... 4,000 shrs @5.90 around 8/8/17; & I added ... " ⭐ I DON'T MAKE FALSE STATEMENTS. ⭐ 我不说谎话不做假. cc: $srne
  • A
    Ariadinvestorg
    $SRNE conversation
    @frankie C 👈 Your Maggot Shield is still not working well. It doesn't shield your husband Yahoo Admin T/Billy at all. It doesn't shield you yourself well, either. Hidden/Covered under/by Dave, you've flirted with me again recently. Hasn't your mirror told you how ugly you are? I have ZERO interest in you. You‘re a shameless 厚颜无耻的无赖贱货!

    .

    This should explain why the 1Q ER forecasted the "weak 2022 outlook" at 6:00 AM (Pacific time 3:00 AM) => https:\\www.nasdaq.com/market-activity/stocks/auph/sec-filings ⭐ Only true longs like Singer/Kurt/sharon/LIT/Dan will be greatly rewarded. The later the buyout, the higher the BO price. There'll be no buyout until it's bought out. ⭐AUPH CEO says "good companies are not sold, they are bought ..."⭐ A great life-saving drug will sell itself well whether it is bought out or goes standalone. No bags, no gold! No patience, no fully filled gold bags! $AUPH $SRNE short squeeze matter of time.
  • A
    Ariadinvestor
    $AUPH conversation
    Yahoo Finance will soon upgrade its message board platform to support my enemy T. 🥂 Cheers, my haters! 🥂 @frankie C 😂 Your husband T is useless. A Yahoo Admin, T has power to delete my posts/accounts. But T hass been being defeated by me since 2012. 我把与敌手对阵当成网上娱乐,同时把它当做学习英文词汇和英文习作的机会。能用从敌手那里学来的英文奚落、挖苦并击败对方,其乐无穷! Taunting provocateurs is my online entertainment/hubby. I am addictive to the online entertainment, fine liquor, English writing practice, telling truths about $SRNE / $AUPH & exposing Yahoo Admin T/Jonny, who bashes/shorts my gold bag stocks. Short squeeze soon?
  • A
    Ariadinvestor
    $AUPH conversation
    @Nad ✔ On 8/10/2020, SRNE closed @ 18.82 (NOT 18.32), I sold @ 18.82 at the closing bell. Yahoo Admin T said again I lost money on $SRNE . Let's me repost my reply to him posted 2- years ago: "I lost money? I took some profits @ $10/$18.82 on 2020-05-18/2020-08-10 'to take out cost basis & free roll it' in K Smooth's words. You bought NIO @ $39? 😁 I bought NK/NIO @ $1.15/$1.99 on 11/08/2019. I took cost basis out by writing covered calls against only 1/3 of my NIO/NK shares 8 months later." ⭐ A falling knife is sweet! ⭐
  • B
    Bruce
    $SRNE conversation
    @Al You should condemn the attackers instead of attacking the counterattackers. Ariadinvestor claims he doesn't attack anyone unless he has been attacked first. TRUE! frankie C has resurfaced & resumed her attacks. Wayne, Ray, edward, Big Toe & Yahoo Admin Billy/K.C/T never stop their attacks. Ariadinvestor counterattacks the attackers. When will the war end?

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .
    cc: $AUPH $SRNE $auph $srne
    .

    Aug 26, 2021 (AB Digital via COMTEX) -- VICTORIA, British Columbia - Aurinia Pharmaceuticals (NASDAQ: $AUPH ) (the “Company”) is pleased to announce that it will enter into a definitive agreement with a pharma behemoth. The leading pharmaceutical company is in talks with AUPH for an acquisition pegged at $35 per American Depositary Share (ADS) or plus.

    On paper, the total consideration of the acquisition is estimated to come up to $4,485 billion in the form of $35 in cash ordinary shares or plus. The transaction has been said to be unanimously approved by the Board of Directors of both companies and is expected to close in the third quarter of 2021.

    “This collaboration will help us pave the way to create many more solutions in the autoimmune space and will be able to increase our marketing process” said Peter Greenleaf, President and Chief Executive Officer of Aurinia Pharmaceuticals speaking about the said merger.

    Founded in 2012, Aurinia Pharmaceuticals Inc specializes in principled drug development and commercialization in the field of autoimmune diseases. The Canadian company’s stocks are currently valued at $14.33 (as of 23 August 2021), and the values are projected to rise with the impending acquisition.

    With a market cap of $2 billion, the Company packs a lot of potential for its original solutions in the field of autoimmune diseases. The merger would come as the perfect progression to the acquiring company that is known to cashing in on strong trends to make deals of economic relevance.

    Various sources and market whispers indicated that multiple pharma companies were keen on exploring acquisition opportunities with $AUPH . However, this market leader was finally the one that converted these interests through its proposal of a tuck-in acquisition.

    Earlier this year, the acquiring company also made investments in the space of oncology. After having spent roughly $1.4 billion in milestone payments the pharma giant was exploring other investments in non-linear pharma fields. AUPH emerged as one of the safest buys on its list.

    As per this proposal, the acquisition indicates a merger of the two companies. Even though the acquiring company is capable of deploying a windfall of cash, a tuck-in acquisition seems ideal for the current market. AUPH has presented itself as the perfect option for the acquiring company to leverage the company’s skills and knowledge.

    The merger will also help $AUPH bring its deep experience in actively pursuing a broader portfolio of innovative drugs for autoimmune diseases like Lupus and Nephritis to the table. A successful tuck-in acquisition can increase revenues and broaden the acquiring company's capabilities and resources, which can effectively boost AUPH’s growth graph.

    The Company launched its first product Lupkynis in January this year. The drug that was made to treat Lupus Nephritis clocked in revenues of $6.6 million in the second quarter superseding pre-launch expectations. $SRNE short squeeze ?

    Recently the company also acquired novel pipeline assets targeting autoimmune and kidney-related diseases diversifying its portfolio of offering therapeutic solutions to people living with rare diseases.

    Once the merger with the market leader goes through, AUPH is expected to bring promising new products to the market keeping up with its offerings in the space of autoimmune diseases.

    About Aurinia

    Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

    Statutory Statement
    $SRNE
    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including statements regarding the underwritten public offering, the amount and anticipated use of proceeds from the offering, those relating to
  • J
    John
    $SRNE conversation
    Jay: "I would ask everyone respectfully to stop bullying Ariadinvestor. He is not short and do not bully anyone unless you start bothering him first. He just like one of us true long. It just breaks uniformity. And there is nothing you can do about him." @Jay This post of yours has been deleted. So I am copying and pasting it to both the $SRNE board and the $AUPH board.
  • A
    Ariadinvestorg
    $SRNE conversation
    @edward/Dr/Rank/Billy/Rodney Hendricks/nunu 👈 Let's swear to God I would burn in hell if I've ever shorted SRNE/AUPH, or your whole clan old & young including the unborn will die the most pain deaths & burn in hell. Although I took profits @ $10 & $18.82 on 05/18/20 & 08/10/20 "to take out cost basis & free roll it" in K Smooth's words, I still own far more than Tim's original 55K shares. Your parents are #$%$. Had I ever counterattacked you before you attacked me first? $AUPH $SRNE short squeeze soon?
  • s
    stocker
    $SRNE conversation
    OT:
    HKD
    did anyone get on it??

    stocker3 days ago
    $SRNE conversation
    OT
    did anyone get on HKD?
    LOL

    Reply1
  • V
    Vic
    $SRNE conversation
    $SRNE conversation
    Seeking Alpha Analysis of PSS Arbitration
    Due Diligence
    I like this since it was the most recent analysis of the arbitration

    Background information from seeking alpha
    The Full Story Why Sorrento Therapeutics Offers Tremendous Upside.
    Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

    • $1 Billion Lawsuit could now be $5 Billion return for Sorrento.

    • The $1 Billion Lawsuit

    • Sorrento has a pending $1 Billion dollar lawsuit against the richest Dr in the world Dr Pattrick Soon-Shiong. Sorrento alleged Soon-Shiong bought and then sought to kill Sorrento’s experimental cancer drug, Cynviloq, before it could reach the market. According to Sorrento, Soon-Shiong’s NantPharma in 2015 acquired the rights to Cynviloq for $90 million cash and agreed to pay an additional $1.2 billion upon the meeting of certain milestones.

    • Cynviloq was undergoing multiple clinical trials to determine its bioequivalence to Abraxane, a cancer drug Soon-Shiong invented, reported Forbes. Soon-Shiong had sold Abraxane maker Abraxis to Celgene Corp in 2010 for $4.5 billion in cash and stock. CEO interview describing how the drug mirrors Abraxane, which gives Sorrento's law suit against Soon-Shiong real credibility seeing as it would be a competitive drug on the market and Soon-Shiong would of needed to pay $1.2 Billion to Sorrento.

    • Sorrento said although Soon-Shiong bought the rights to Cynviloq, he then halted the process of bringing the drug to the market, thereby reducing competition for Abraxane. The complaint said that Soon-Shiong did not pursue relevant FDA approvals for Cynviloq and let “critical patents lapse” “demonstrating zero interest in reaching the approvals the parties had agreed upon in their sale agreement,”.

    • While Soon-Shiong no longer owned Abraxane, he was still Celgene’s largest individual stockholder holding 1.5 billion worth of stock valued in 2015, so a new competitor to Abraxane would have been “financially devastating” to Soon-Shiong, which the lawsuit alleged.

    • The suit also alleges that Soon-Shiong arranged a separate scheme to get back the $90 million he had paid Sorrento in 2015. Sorrento said it invested $40 million of the $90 million it received from NantPharma to form a joint venture with Soon-Shiong’s NantCell, focused on cancer immunotherapy treatments. Two years later, Soon-Shiong and his chief legal officer, Charles Kim, who is also named as a defendant in Sorrento’s suit, signed a “secret deal” to move nearly all of Sorrento's $40 million out of the joint venture and over into NantPharma, without Sorrento's knowledge

    • Judge sides with Sorrento, October 2019 Los Angeles Superior Court judge rejected Patrick Soon-Shiong’s attempt to allow him and his company, NantPharma, to avoid the billion-dollar fraud and breach of contract claims that Sorrento filed against them earlier in the year. Sorrento’s claims relate to the “catch and kill” scheme that Soon-Shiong allegedly orchestrated to keep Sorrento’s promising cancer drug, Cynviloq, off the market in order to preserve Soon-Shiong’s personal financial interest in another competing drug.

    • The Los Angeles Superior Court Judge ruled among other things, denied Soon-Shiong’s and NantPharma’s motion to stay or dismiss Sorrento’s arbitration against them, thus allowing the case to proceed in full. The Court also granted Sorrento’s motions to compel Soon-Shiong entity NantCell’s counterclaims to arbitration, rejecting NantCell’s attempts to avoid the arbitration agreement it had previously entered into with Sorrento.

    • Again watch CEO interview describing how the drug mirrors Abraxane the interview proves Sorrento has a very good case and why the drug should of been brought to market.

    • Update On March 6, 2020 after the stock market closed Sorrento disclosed that the company had filed a legal action against Patrick Soon-Shiong in Los Angeles Superior Court, asserting claims for fraudulent inducement and common law fraud, arising out of Dr. Soon-Shiong’s purchase of the drug CynviloqTM from the Company in May 2015. The action alleges that, among other things, Dr. Soon-Shiong acquired the drug Cynviloq for the purpose of halting its progression to the market.

    -Post-Hearing Submissions: After the hearing, both parties may present additional documentation, as allowed by the arbitrator.

    -The Award: Finally, the arbitrator closes the record on the case and issues a decision, including an award, if applicable the right to a jury trial against Dr. Soon-Shiong, the Company has dismissed Dr. Soon-Shiong from the related, ongoing arbitration against NantPharma, LLC.

    • I discussed this with my attorney friend he feels this is excellent news and good advice from Sorrento's legal team he suggested Dr Patrick Soon-Shiong could very well pay much much more possibly 5 times the original $1 billion arbitration suit, reason being is a jury could take severe action against Soon-Shiong for keeping a cancer dr
  • s
    stocker
    $SRNE conversation
    stocker13 days ago
    $SRNE conversation
    warning to shorties
    dont let it get past 2.66-2.71
    or she is headed to 4.32-4.57
    IMHO
  • H
    Hope
    $SRNE conversation
    $SRNE

    Yet another highly infectious Omicron variant is raising concerns in India and
    https://www.latimes.com/world-nation/story/2022-07-11/new-coronavirus-omicron-subvariant-concerns
  • J
    Jon
    $SRNE conversation
    Ariadinvestor claims he does not attack anyone unless he has been attacked first. TRUE! frankie C has resurfaced and resumed her attacks. Doug is an new attacker. Wayne, Ray, David, nunu, Big Toe & Yahoo Admin Todd/T/jim never stop their attacks. We can find THE TRUTH by switching to "Newest Reactions". Ariadinvestor counterattacks the attackers. When will the war end?

    "
    cc: $AUPH $SRNE $auph $srne
    ---------------
    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    .

    Aug 26, 2021 (AB Digital via COMTEX) -- VICTORIA, British Columbia - Aurinia Pharmaceuticals (NASDAQ: $AUPH ) (the “Company”) is pleased to announce that it will enter into a definitive agreement with a pharma behemoth. The leading pharmaceutical company is in talks with AUPH for an acquisition pegged at $35 per American Depositary Share (ADS) or plus.

    On paper, the total consideration of the acquisition is estimated to come up to $4,485 billion in the form of $35 in cash ordinary shares or plus. The transaction has been said to be unanimously approved by the Board of Directors of both companies and is expected to close in the third quarter of 2021.

    “This collaboration will help us pave the way to create many more solutions in the autoimmune space and will be able to increase our marketing process” said Peter Greenleaf, President and Chief Executive Officer of Aurinia Pharmaceuticals speaking about the said merger.

    Founded in 2012, Aurinia Pharmaceuticals Inc specializes in principled drug development and commercialization in the field of autoimmune diseases. The Canadian company’s stocks are currently valued at $14.33 (as of 23 August 2021), and the values are projected to rise with the impending acquisition.

    With a market cap of $2 billion, the Company packs a lot of potential for its original solutions in the field of autoimmune diseases. The merger would come as the perfect progression to the acquiring company that is known to cashing in on strong trends to make deals of economic relevance.

    Various sources and market whispers indicated that multiple pharma companies were keen on exploring acquisition opportunities with $AUPH . However, this market leader was finally the one that converted these interests through its proposal of a tuck-in acquisition.

    Earlier this year, the acquiring company also made investments in the space of oncology. After having spent roughly $1.4 billion in milestone payments the pharma giant was exploring other investments in non-linear pharma fields. AUPH emerged as one of the safest buys on its list.

    As per this proposal, the acquisition indicates a merger of the two companies. Even though the acquiring company is capable of deploying a windfall of cash, a tuck-in acquisition seems ideal for the current market. AUPH has presented itself as the perfect option for the acquiring company to leverage the company’s skills and knowledge.

    The merger will also help $AUPH bring its deep experience in actively pursuing a broader portfolio of innovative drugs for autoimmune diseases like Lupus and Nephritis to the table. A successful tuck-in acquisition can increase revenues and broaden the acquiring company's capabilities and resources, which can effectively boost AUPH’s growth graph.

    The Company launched its first product Lupkynis in January this year. The drug that was made to treat Lupus Nephritis clocked in revenues of $6.6 million in the second quarter superseding pre-launch expectations. $SRNE short squeeze ?

    Recently the company also acquired novel pipeline assets targeting autoimmune and kidney-related diseases diversifying its portfolio of offering therapeutic solutions to people living with rare diseases.

    Once the merger with the market leader goes through, AUPH is expected to bring promising new products to the market keeping up with its offerings in the space of autoimmune diseases.

    About Aurinia

    Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

    Statutory Statement
    $SRNE
    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including statements regarding the underwritten public offering, the amount and anticipated use of proceeds from the offering, those relating to Company's product development, clinical and regulatory timelines, market opportunity, competitive
  • s
    stocker
    $SRNE conversation
    Come on shorties..u aint posting enuff

    """stocker 14 hours ago
    $SRNE conversation
    shorties...just like you gave the 2.23-2.42 a good test on july 12 (on my command..thanks..LOL)..its time for you to give the 2.66-2.71 a good test...
    make sure you come out guns ablaaaaaaazing with your posts when that happens...Thanks

    """"""""""""""
  • s
    stocker
    $SRNE conversation
    stocker 13 days ago
    $SRNE conversation
    The same TA pattern we saw on the daily charts before the rise in SRNE
    That same TA pattern is about to happen on the weekly charts.
  • s
    stocker
    $SRNE conversation
    This post got 191 thumbs down yesterday.. LOL

    """"stocker 21 hours ago
    $SRNE conversation
    News Release
    Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19
    July 19, 2022 at 2:53 PM EDT"""""
  • A
    Ariadinvestor
    $SRNE conversation
    @T/Todd/jim ✔"History repeats itself. Both you & I are repeating the Ariad war. I won it as Ariad’s science & pipeline eventually won. I will also win the $AUPH / $SRNE wars as time will let you know it. Will you declare defeating me again by abusing your Yahoo Admin power & deleting my posts/accounts? You’ve left tons of evidences for Verizon to get sued. You don't care about losing your 1st job as a Yahoo Admin because you get paid more from your 2nd job as a paid basher, right? Didn't you say ARIA would drop to $2 & bankrupt right before the $24 buyout?" I've been posting this since 7/5/19.